SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Martek Biosciences Corp – ‘8-K’ for 6/3/03

On:  Tuesday, 6/3/03, at 4:19pm ET   ·   For:  6/3/03   ·   Accession #:  950133-3-2084   ·   File #:  0-22354

Previous ‘8-K’:  ‘8-K’ on / for 4/8/03   ·   Next:  ‘8-K’ on 7/22/03 for 7/21/03   ·   Latest:  ‘8-K’ on 2/25/11 for 2/18/11

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/03/03  Martek Biosciences Corp           8-K:7,9     6/03/03    2:84K                                    Bowne - DC/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     11K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     70K 


8-K   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  e8vk  

 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2003

Martek Biosciences Corporation
(Exact name of registrant as specified in its charter)
         
Delaware   000-22354   52-1399362

(State or other jurisdiction of   (Commission File   (I.R.S. Employer
incorporation)   Number)   Identification No.)
         
6480 Dobbin Road Columbia, Maryland     21045  

(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (410) 740-0081


(Former name or former address, if changed since last report)

 


 



 

MARTEK BIOSCIENCES CORPORATION

Item 7. Financial Statements and Exhibits.

(c)  Exhibits

  Exhibit 99.1 - Press Release issued by Martek Biosciences Corporation (“Martek”), dated June 3, 2003.

Item 9. Regulation FD Disclosure (Information Provided Under Item 12 Results of Operations and Financial Condition).

          On June 3, 2003, Martek issued a press release announcing its financial results for the fiscal quarter ended April 30, 2003. A copy of Martek’s press release is attached hereto as Exhibit 99.1.

          The information contained herein and in the accompanying exhibit is furnished pursuant to Item 12 (Results of Operations and Financial Condition) in accordance with interim guidance issued by the Securities and Exchange Commission in Release No. 33-8216.

- 2 -



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
        MARTEK BIOSCIENCES CORPORATION
 
Date: June 3, 2003   By:   /s/ Peter L. Buzy

      Peter L. Buzy
      Chief Financial Officer

- 3 -



 

Exhibit Index

99.1      Press Release dated June 3, 2003 issued by Martek Biosciences Corporation

- 4 -


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period End:6/3/03
4/30/0310-Q
 List all Filings 
Top
Filing Submission 0000950133-03-002084   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 1:11:07.1am ET